4 Covid-19 vaccine candidates in human trial stage, 1 in pre-clinical stage, Govt tells Rajya Sabha

In a written response to a question in the Rajya Sabha, Jitendra Singh said Cadila Healthcare Ltd's DNA-based vaccine candidate is in phase three clinical trial

4 Covid-19 vaccine candidates in human trial stage, 1 in pre-clinical stage, Govt tells Rajya Sabha

This picture has been used for representational purpose. Pic/AFP

Four Covid-19 vaccine candidates are at different stages of human trials while one, developed by Genique Life Sciences, is in the advanced pre-clinical stage, Union Science and Technology Minister Jitendra Singh said.

In a written response to a question in the Rajya Sabha, Singh said Cadila Healthcare Ltd's DNA-based vaccine candidate is in phase three clinical trial. It has also submitted the interim data for emergency use authorisation. Biological E Ltd's vaccine candidate is also in phase three clinical trial. Bharat Biotech International Ltd's Adeno intranasal vaccine candidate is in phase three clinical trial, while Gennova Biopharmaceuticals Ltd's mRNA-vaccine candidate is in Phase one clinical trial.

The Gurugram-based Genique Life Sciences Pvt Ltd's vaccine candidate is in the advanced pre-clinical stage, Singh said. Currently, three vaccines --- Serum Institute of India's Covishield, Bharat Biotech's Covaxin and Russian vaccine Sputnik V are being administered in India.

Also Read: Home Covid-19 vaccination for bed-ridden people to start in Mumbai from August 1: Maha govt tells Bombay HC

Singh said 'Mission Covid Suraksha -- the Indian Covid-19 Vaccine Development Mission' was announced as part of the third stimulus package 'Atmanirbhar Bharat 3.0' for promoting research and development of Indian Covid-19 vaccines. "The mission is supporting the development of four vaccine candidates in the clinical stage of development and one vaccine candidate in advance pre-clinical stage of development. "The clinical development of vaccine candidates is being undertaken across the clinical trial sites situated pan-India," he added.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels